Dr. Minghui Zhang 张明辉
Chief Physician, Lecturer
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, and immunotherapy for lung cancer, with a focus on recurrent and metastatic lung adenocarcinoma, squamous cell carcinoma, and small cell lung cancer.
Dr. Zhang holds an MD and completed postdoctoral training at Harbin Medical University Cancer Hospital. As a master's supervisor, Dr. Zhang focuses on chemotherapy, targeted therapy, and immunotherapy for lung cancer. Dr. Zhang has published multiple papers in national journals and SCI-indexed journals.
Name order: in Chinese the family name comes first (Zhang Minghui). Papers usually list the name as Minghui Zhang or Zhang M.
Selected publications
43 papers on PubMed matched by name and affiliation; 15 as first or senior author since 2016. Most recent first- or senior-author papers:
- Lung Cancer, 2026 (first author): First-line camrelizumab plus chemotherapy followed by camrelizumab-apatinib maintenance for ES-SCLC: a single-arm phase II study. PubMed 42767923
- Cell Rep Med, 2026 (senior author): Single-cell spatial analysis stratifies lung adenocarcinoma with rare actionable mutations and reveals immune-modulatory cellular crosstalk. PubMed 42013848
- Drug Resist Updat, 2026 (first author): Tumor immune organoids in immunotherapy resistance and drug screening. PubMed 41604831
- Crit Rev Oncol Hematol, 2025 (senior author): Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer. PubMed 40024354
- Front Immunol, 2022 (first author): CD8(+) T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma. PubMed 35273597
- Front Oncol, 2019 (first author): An Immune-Related Signature Predicts Survival in Patients With Lung Adenocarcinoma. PubMed 31921619
- J Cancer, 2018 (senior author): Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms. PubMed 30310505
- Pathol Oncol Res, 2018 (senior author): VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer. PubMed 28744693
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion